Nintedanib esylate
Nintedanib esylate (CAS: 656247-18-6) is the ethanesulfonate salt of nintedanib, a small-molecule tyrosine kinase inhibitor targeting VEGFR, PDGFR, and FGFR receptors. By blocking these angiogenic and fibrogenic signaling pathways, it inhibits the proliferation and migration of endothelial and perivascular cells, making it effective in oncology and fibrotic disease treatment. It is approved for the treatment of idiopathic pulmonary fibrosis, other chronic fibrosing interstitial lung diseases, and in combination with docetaxel for second-line non-small cell lung cancer. The esylate salt form optimizes oral bioavailability, solubility, and formulation stability in soft gelatin capsule presentations. As a prescription active pharmaceutical ingredient, it is manufactured under GMP conditions with comprehensive quality assurance. Its targeted mechanism and oral dosing convenience have established nintedanib as an important therapeutic option in pulmonary medicine and oncology.
– Pulmonary Fibrosis Treatment: Used as an antifibrotic agent slowing disease progression in idiopathic pulmonary fibrosis and progressive interstitial lung diseases.
– Oncology Applications: Approved in combination regimens for second-line treatment of advanced non-small cell lung cancer and other solid tumors.
– Oral Capsule Formulations: Supplied as the esylate salt for soft gelatin capsule delivery ensuring consistent bioavailability and patient compliance.
Product Name: Nintedanib esylate
For global customers, we provide complete technical documentation to support product evaluation, regulatory compliance and safe handling during transportation and application.